WYE-354 is a cell-permeable pyrazolopyrimidine compound that acts as a potent and ATP-competitive mTOR inhibitor (IC50 = 5 nM with S6K as the substrate and 100 µM ATP).
WYE-354 is a cell-permeable pyrazolopyrimidine compound that acts as a potent and ATP-competitive mTOR inhibitor (IC50 = 5 nM with S6K as the substrate and 100 µM ATP).
WYE-354 is a cell-permeable pyrazolopyrimidine compound that acts as a potent and ATP-competitive mTOR inhibitor (IC50 = 5 nM with S6K as the substrate and 100 µM ATP).
WYE-354 is a cell-permeable pyrazolopyrimidine compound that acts as a potent and ATP-competitive mTOR inhibitor (IC50 = 5 nM with S6K as the substrate and 100 µM ATP).
WYE-687 is a novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin (mTOR) with an IC50 of 7 nM.
WYE-687 is a novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin (mTOR) with an IC50 of 7 nM.
WYE-687 is a novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin (mTOR) with an IC50 of 7 nM.
WYE-687 is a novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin (mTOR) with an IC50 of 7 nM.
WYE-687 is a novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin (mTOR) with an IC50 of 7 nM.
WYRGRL is a collagen type II-binding peptide. The WYRGRL peptide has an inherent affinity for the cartilage matrix component of collagen II protein.
WYRGRL is a collagen type II-binding peptide. The WYRGRL peptide has an inherent affinity for the cartilage matrix component of collagen II protein.
WZ811 is a highly competitive CXCR4 antagonist with oral activity. WZ811 effectively inhibited CXCR4/SDF-1 (also known as CXCL12) -mediated regulation of cAMP level (EC50=1.2 nM) and SDF-1-induced matrix glue invasion (EC50=5.2 nM) in cells.